Organon (OGN) Rises Higher Than Market: Key Facts
The latest trading day saw Organon (OGN) settling at $9.33, representing a +1.3% change from its previous close.
Organon (OGN) Stock Drops Despite Market Gains: Important Facts to Note
In the latest trading session, Organon (OGN) closed at $8.54, marking a -3.28% move from the previous day.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
This Women's Healthcare Stock Is Up 15% on Reports of a Takeover In the Works
Organon shares are popping Friday on signs of a takeover deal.
Organon (OGN) Stock Sinks As Market Gains: Here's Why
In the most recent trading session, Organon (OGN) closed at $6.05, indicating a -4.87% shift from the previous trading day.
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Organon (OGN) Suffers a Larger Drop Than the General Market: Key Insights
In the latest trading session, Organon (OGN) closed at $5.84, marking a -3.47% move from the previous day.
Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know
Organon (OGN) closed at $6.23 in the latest trading session, marking a -2.5% move from the prior day.
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
OGN's VTAMA Cream Shows Sleep Benefits in Pediatric Atopic Dermatitis
Organon reports Phase 3 data showing VTAMA improved sleep in children as young as two with atopic dermatitis, reinforcing its dermatology push.
Organon: Revenue Decline, Margin Pressure, And Strategic Uncertainty
Organon reported a disappointing Q4, with revenue down 5% YoY and significant weakness in women's health. Shares are heavily oversold, but I maintain a Hold rating due to strategic uncertainty and lack of near-term catalysts. Management prioritizes debt reduction and margin preservation over growth, with no revenue improvement expected through 2026.
Organon Q4 Earnings Review: Poor Results Trigger Predictable Sell-Off
Organon reported disappointing 2025 results, with revenues down 3% and no growth expected in 2026. OGN faces potentially terminal declines in established brands, flat biosimilar growth, and underwhelming Women's Health performance, all compounded by ~$8bn in net debt. The dividend was slashed last year to $0.02/quarter, a yield of now ~1%, with capital allocation constrained by high-interest expenses and limited M&A capacity.
